3 reports

  • the Company obtains new clinical evidence that supports BTD.
  • AXALIMOGENE FILOLISBAC - DRUG PROFILE

In a second poster entitled, " Targeting of phosphatidylserine by monoclonal antibodies enhances the activity of immune checkpoint inhibitors in breast tumors, " Peregrine researchers presented data demonstrating that PS blockade enhances the anti-tumor activity of combinat

  • Cancer
  • Monoclonal Antibody
  • United States
  • Product Initiative
  • Advaxis, Inc.
  • AXALIMOGENE FILOLISBAC - DRUG PROFILE

IN A SECOND POSTER ENTITLED, " TARGETING OF PHOSPHATIDYLSERINE BY MONOCLONAL ANTIBODIES ENHANCES THE ACTIVITY OF IMMUNE CHECKPOINT INHIBITORS IN BREAST TUMORS, " PEREGRINE RESEARCHERS PRESENTED DATA DEMONSTRATING THAT PS BLOCKADE ENHANCES THE ANTI-TUMOR ACTIVITY OF COMBINAT

  • Cancer
  • Hospital
  • Monoclonal Antibody
  • Therapy
  • Advaxis, Inc.
  • Other Developmental Activities
  • Discovery/Preclinical Trial Details

SLC is also developing a backup small molecule inhibitor of CAIX (SLC-##) and in collaboration with the National Research Council of Canada, a monoclonal antibody (SLC-##) targeting CAIX.

  • Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • Vaccine
  • Advaxis, Inc.